PARP inhibitors as a new therapeutic option in metastatic prostate cancer: a systematic review

Subjects

Abstract

Background

A great number of DNA-damage repair (DDR) pathways have been recognized to be frequently dysregulated in advanced stages of prostate cancer. DNA-repair defects in prostate cancer represents a clinically relevant disease subset. Tumors whose ability to repair double-strand DNA breaks by homologous recombination is compromised, are highly sensitive to blockade of the repair of DNA single-strand breaks via the inhibition of the enzyme poly(ADP) ribose polymerase (PARP).

Methods

A systematic review of the literature has been conducted in January 2020 using PubMed Medline database in line with the recommendations from the PRISMA guidelines. The following string terms were used for searching clinical trial articles: castration resistant OR castrate resistance OR castration refractory AND prostate cancer AND PARP OR poly(ADP-ribose) polymerase inhibitor OR DNA-repair OR homologous recombination repair. On-going clinical trials with olaparib, niraparib, talazoparib, veliparib, and rucaparib in mCRPC were searched on the clinicalTrials.gov website.

Results

From this research 176 articles were identified. After title screening and abstract reading, five papers and four abstract were considered for the systematic review. Thirty-two clinical trials were also identified: from these 16 trials which did not include mCRPC patients or only prostate cancer patients, trials not yet recruiting and trials including radio-metabolic treatments were excluded. Sixteen trials were included and discussed in the paper.

Conclusions

Olaparib has been the first agent showing a benefit in terms of rPFS and ORR alone or in combination with abiraterone plus prednisone in patients with DDR deficiency prostate cancer. Also rucaparib showed a benefit in terms of PSA response rate and ORR in patients with BRCA2 and BRCA1 mutation in a phase-II study. Other phase-III clinical trials are evaluating niraparib and talazoparib, alone or in combination with AR signaling inhibitors.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1: PARP mechanism and inhibition.
Fig. 2: Article’s selection process: the PRISMA flow chart.

References

  1. 1.

    Rawla P. Epidemiology of prostate cancer. World J Oncol. 2019;10:63–89.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  2. 2.

    Tan MH, Li J, Xu HE, Melcher K, Yong EL. Androgen receptor: structure, role in prostate cancer and drug discovery. Acta Pharm Sin. 2015;36:3–23.

    CAS  Article  Google Scholar 

  3. 3.

    Jeggo PA, Pearl LH, Carr AM. DNA repair, genome stability and cancer: a historical perspective. Nat Rev Cancer. 2016;16:35–42.

    CAS  PubMed  Article  Google Scholar 

  4. 4.

    Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N Engl J Med. 2016;375:443–53.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  5. 5.

    Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol J Am Soc Clin Oncol. 2008;26:3785–90.

    CAS  Article  Google Scholar 

  6. 6.

    Krishnakumar R, Kraus WL. The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets. Mol Cell. 2010;39:8–24.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  7. 7.

    Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, et al. Integrative clinical genomics of advanced prostate. Cancer Cell. 2015;161:1215–28.

    CAS  Google Scholar 

  8. 8.

    Cancer Genome Atlas Research Network The molecular taxonomy of primary prostate cancer. Cell. 2015;163:1011–25.

    Article  CAS  Google Scholar 

  9. 9.

    Martin ST, Matsubayashi H, Rogers CD, Philips J, Couch FJ, Brune K, et al. Increased prevalence of the BRCA2 polymorphic stop codon K3326X among individuals with familial pancreatic cancer. Oncogene. 2005;24:3652–6.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  10. 10.

    Farrugia DJ, Agarwal MK, Pankratz VS, Deffenbaugh AM, Pruss D, Frye C, et al. Functional assays for classification of BRCA2 variants of uncertain significance. Cancer Res. 2008;68:3523–31.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  11. 11.

    Blazek D, Kohoutek J, Bartholomeeusen K, Johansen E, Hulinkova P, Luo Z, et al. The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes. BM Genes Dev. 2011;25:2158–72.

    CAS  Article  Google Scholar 

  12. 12.

    Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature. 2012;487:239–43.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  13. 13.

    Armenia J, Wankowicz SAM, Liu D, Gao J, Kundra R, Reznik E, et al. The long tail of oncogenic drivers in prostate cancer. Nat Genet. 2018;50:645–51.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  14. 14.

    Castro E, Goh C, Olmos D, Saunders E, Leongamornlert D, Tymrakiewicz M, et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol. 2013;31:1748–57.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  15. 15.

    Castro E, Goh C, Leongamornlert D, Saunders E, Tymrakiewicz M, Dadaev T, et al. Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localised prostate cancer. Eur Urol. 2015;68:186–93.

    CAS  PubMed  Article  Google Scholar 

  16. 16.

    Page EC, Bancroft EK, Brook MN, Assel M, Hassan Al Battat M, Thomas S, et al. Interim results from the IMPACT Study: evidence for prostate-specific antigen screening in BRCA2 mutation carriers. Eur Urol. 2019;76:831–42.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  17. 17.

    Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. J Clin Epidemiol. 2009;62:1006–12.

    PubMed  Article  Google Scholar 

  18. 18.

    Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, et al. DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med. 2015;373:1697–708.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  19. 19.

    Mateo J, Porta N, Bianchini D, McGovern U, Elliott T, Jones R, et al. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2020;21:162–74.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  20. 20.

    Hussain M, Mateo J, Fizazi K, Saad F, Shore ND, Sandhu S, et al. PROfound: Phase 3 study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations. Ann Oncol. 2019;30(Suppl_5):v851–934.

    Google Scholar 

  21. 21.

    Polkinhorn WR, Parker JS, Lee MX, Kass EM, Spratt DE, Iaquinta PJ, et al. Androgen receptor signaling regulates DNA repair in prostate cancers. Cancer Discov. 2013;3:1245–53.

    Article  CAS  Google Scholar 

  22. 22.

    Schiewer MJ, Goodwin JF, Han S, Brenner JC, Augello MA, Dean JL, et al. Dual roles of PARP-1 promote cancer growth and progression. Cancer Discov 2012;2:1134–49.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  23. 23.

    Hussain M, Daignault-Newton S, Twardowski PW, Albany C, Stein MN, Kunju LP, et al. Targeting androgen receptor and DNA repair in metastatic castration-resistant prostate cancer: results From NCI 9012. J Clin Oncol. 2018;36:991–9.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  24. 24.

    Antonarakis ES, Lu C, Luber B, Liang C, Wang H, Chen Y, et al. Germline DNA-repair gene mutations and outcomes in men with metastatic castration-resistant prostate cancer receiving first-line abiraterone and enzalutamide. Eur Urol. 2018;74:218–25.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  25. 25.

    Clarke N, Wiechno P, Alekseev B, Sala N, Jones R, Kocak I, et al. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2018;19:975–86.

    CAS  PubMed  Article  Google Scholar 

  26. 26.

    Chabanon RM, Muirhead G, Krastev DB, Adam J, Morel D, Garrido M, et al. PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer. J Clin Investig. 2019;129:1211–28.

    PubMed  Article  PubMed Central  Google Scholar 

  27. 27.

    Barber GN. STING: infection, inflammation and cancer. Nat Rev Immunol. 2015;15:760–70.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  28. 28.

    Yu EY, Massard C, Retz M, Tafreshi A, Galceran JC, Hammerer P, et al. Keynote-365 cohort a: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC). J Clin Oncol. 2019;37(Suppl. 7):145.

    Article  Google Scholar 

  29. 29.

    Karzai F, VanderWeele D, Madan RA, Owens H, Cordes LM, Hankin A, et al. Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations. J Immunother Cancer. 2018;6:141.

    PubMed  PubMed Central  Article  Google Scholar 

  30. 30.

    Abida W, Campbell D, Patnaik A, Sautois B, Shapiro J, Vogelzang NJ, et al. Preliminary results from the TRITON2 study of rucaparib in patients (pts) with DNA damage repair (DDR)-deficient metastatic castration-resistant prostate cancer (mCRPC): updated analyses. Ann Oncol. 2019;30(Suppl 5):mdz248.003.

    Google Scholar 

  31. 31.

    Smith MR, Sandhu SK, Kelly WK, Scher HI, Efstathiou E, Lara PN, et al. Pre-specified interim analysis of GALAHAD: a phase 2 study of niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD). Ann Oncol. 2019;30(Suppl. 5):v851–934.

    Google Scholar 

  32. 32.

    Kumar-Sinha C, Tomlins SA, Chinnaiyan AM. Recurrent gene fusions in prostate cancer. Nat Rev Cancer. 2008;8:497–511.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  33. 33.

    Hussain M, Carducci MA, Slovin S, Cetnar J, Qian J, McKeegan EM, et al. Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer. Investig New Drugs. 2014;32:904–12.

    CAS  Article  Google Scholar 

  34. 34.

    Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373:737–46.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  35. 35.

    James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387:1163–77.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  36. 36.

    Ratta R, Grassi P, Fucà G, Verzoni E, Procopio G. Castration-naive metastatic prostate cancer: reshaping old paradigms. Expert Rev Anticancer Ther. 2017;17:879–81.

    CAS  PubMed  Article  Google Scholar 

  37. 37.

    Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377:352–60.

    CAS  PubMed  Article  Google Scholar 

  38. 38.

    James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377:338–51.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  39. 39.

    Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med. 2019;381:13–24.

    CAS  PubMed  Article  Google Scholar 

  40. 40.

    Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med. 2019;381:121–31.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  41. 41.

    Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, et al. ARCHES: a randomized, Phase III Study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2019;37:2974–86.

    PubMed  Article  PubMed Central  Google Scholar 

  42. 42.

    Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U, et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2018;378:2465–74.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  43. 43.

    Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med. 2018;378:1408–18.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  44. 44.

    Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2019;380:1235–46.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

Download references

Acknowledgements

The authors thank Dr Pontoni Giancarlo for the graphical support.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Raffaele Ratta.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Ratta, R., Guida, A., Scotté, F. et al. PARP inhibitors as a new therapeutic option in metastatic prostate cancer: a systematic review. Prostate Cancer Prostatic Dis (2020). https://doi.org/10.1038/s41391-020-0233-3

Download citation

Further reading

  • The emerging role of PARP inhibitors in prostate cancer

    • Marco Stellato
    • , Valentina Guadalupi
    • , Pierangela Sepe
    • , Alessia Mennitto
    • , Mélanie Claps
    • , Emma Zattarin
    • , Elena Verzoni
    • , Riccardo Valdagni
    • , Filippo Gm De Braud
    • , Daniele Santini
    • , Giuseppe Tonini
    •  & Giuseppe Procopio

    Expert Review of Anticancer Therapy (2020)